A unique webinar on Cerebral Amyloid Angiopathy emerging diagnostic advances, by people who are driving these changes in the field. No similar session has been recently presented in international conferences as such, and there is a lot of uncertainty among stroke neurologists and other clinicians around CAA diagnosis, emerging biomarkers and more rare presentations.
Cerebral amyloid angiopathy is a common small vessel disease of the brain, associated with high risk of lobar intracerebral hemorrhage and dementia. An accurate diagnosis of cerebral amyloid angiopathy during life is therefore important for both clinical care and research enrolment. There is still a lot of uncertainty among stroke and cognitive neurologists as well as other clinicians around cerebral amyloid angiopathy diagnosis, emerging biomarkers and no so common presentations. We have designed a unique webinar on cerebral amyloid angiopathy emerging diagnostic advances, by clinical researchers who are driving these changes in the field. We will cover selected clinical relevant perspectives including advances in the Boston criteria, diagnosis of amyloid spells and the role of CSF and PET biomarkers.
Cerebral amyloid angiopathy: update on the Boston Criteria (Andreas Charidimou, USA)
Cerebral amyloid angiopathy-related transient focal neurological episodes (Eric Smith, Canada)
CSF and PET biomarkers for cerebral amyloid angiopathy diagnosis (Gargi Banerjee, UK)
4 PM CET on 1st March, 2022
Andreas Charidimou (Boston Medical Centre, Boston University, USA)
Eric Smith (University of Calgary, Canada)
Gargi Banerjee (UCL, London, UK)
Stephanie Debette (Lariboisière Hospital and University Paris Diderot, Paris, France)
Jean-Claude Baron (University of Cambridge, UK)
Corporate Supporters
Corporate Supporters
Platinum Plus
Platinum Plus
Silver
Silver
Silver
Silver
Silver
Bronze
Bronze
Bronze
Bronze
Member login